Presentation Theater: Advanced Formulation of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer, mCRPC


Yonsa, a novel, fine-particle formulation of abiraterone acetate, provides an oral treatment option, in combination with methylprednisolone, for patients with metastatic CRPC. In clinical trials, 500-mg dosing of the fine-particle abiraterone acetate formulation in combination with 4-mg of methylprednisolone demonstrated therapeutic equivalence to 1000-mg dosing of the original formulation, with similar reductions in PSA.

David Berz, MD, PhD, MPH

Presented by Sun Pharmaceutical Industries.


Interest: Presentation Theater
Session Time Slot(s): 
Tuesday, October 29
6:00 PM - 7:30 PM
Hilton Anatole Dallas - Cortez A